Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.


an alkaloid from Colchicum autumnale (meadow saffron), used in treatment of gout, including for termination of an attack of acute gout. Side effects include gastrointestinal symptoms and hypotension.



Pharmacologic class: Colchicum alkaloid

Therapeutic class: Antigout drug

Pregnancy risk category C


Unclear. Antigout action may occur through white blood cell (WBC) migration and reduced lactic acid production by WBCs. This action in turn decreases uric acid deposition, kinetin formation, and phagocytosis, leading to reduction in inflammatory response.


Tablets: 0.6 mg

Indications and dosages

Prophylaxis of gout flares

Adults and adolescents age 16 and older: 0.6 mg P.O. daily or b.i.d. Maximum dosage, 1.2 mg/day.

Treatment of gout flares

Adults and adolescents age 16 and older: 1.2 mg P.O. at first sign of a gout flare, followed by 0.6 mg 1 hour later. Wait 12 hours; then resume prophylactic dose.

Familial Mediterranean fever

Adults and adolescents age 12 and older: 1.2 to 2.4 mg P.O. in one or two divided doses. Increase or decrease dosage as indicated and as tolerated in increments of 0.3 mg/day; not to exceed the maximum recommended daily dosage.

Children ages 6 to 12: 0.9 to 1.8 mg P.O. as a single dose or as divided doses b.i.d.

Children ages 4 to 6: 0.3 to 1.8 mg P.O. as a single dose or as divided doses b.i.d.

Dosage adjustment

• Mild hepatic or renal impairment

Off-label uses

• Hepatic cirrhosis

• Chronic progressive multiple sclerosis

• Pyoderma gangrenosum associated with Crohn's disease

• Psoriasis

• Dermatitis herpetiformis


• Hypersensitivity to drug

• Blood dyscrasias

• Serious GI, renal, hepatic, or cardiac disorders

• Concurrent use of P-glycoprotein or strong CYP3A4 inhibitors (including all protease inhibitors except fosamprenavir)


Use cautiously in:

• renal impairment

• elderly or debilitated patients

• pregnant or breastfeeding patients

• children (safety not established).


• Give tablets without regard to meals.

• Know that GI reactions may be troublesome in patients with peptic ulcer or irritable bowel.

Adverse reactions

CNS: peripheral neuritis, neuropathy

GI: nausea, vomiting, diarrhea, abdominal pain

GU: anuria, hematuria, reversible azoospermia, renal impairment

Hematologic: purpura, agranulocytosis, aplastic anemia, thrombocytopenia

Metabolic: vitamin B12 malabsorption

Musculoskeletal: myopathy

Skin: dermatosis, alopecia

Other: hypersensitivity reactions


Drug-drug. Cyclosporine: colchicine-induced myopathy

Vitamin B12: reversible vitamin malabsorption

Drug-diagnostic tests. Alkaline phosphatase, aspartate aminotransferase: increased levels

Hematocrit, hemoglobin, platelets: decreased values

Urine hemoglobin, urinary red blood cells: false-positive results

Drug-food. Caffeine-containing foods and beverages: decreased colchicine effect

Drug-herbs. Herbal teas, St. John's wort: decreased drug effect

Drug-behaviors. Alcohol use: increased uric acid level

Patient monitoring

Monitor patient for signs and symptoms of toxicity (nausea, vomiting, abdominal pain, bloody diarrhea, burning sensation, muscle weakness, oliguria, hematuria, ascending paralysis, delirium, and seizures). Discontinue drug if these occur.

• Monitor CBC and renal function test results regularly.

• Be aware that patient may need opioids to control drug-induced diarrhea (especially if he's receiving maximum colchicine dosage).

Patient teaching

• Tell patient to take tablets with or without food.

• Instruct patient to report rash, sore throat, fever, tiredness, weakness, numbness, or tingling.

Tell patient to immediately report muscle tremors, weakness, fatigue, bruising, bleeding, yellowing of eyes or skin, pale stools, dark urine, severe vomiting, watery or bloody diarrhea, or abdominal pain.

• Advise patient to increase fluid intake to prevent renal calculi (unless prescriber wants him to restrict fluids).

• Instruct patient to avoid alcohol, herbal teas, and caffeine during therapy.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.


(kol'chi-sin), [USP]
An alkaloid obtained from Colchicum autumnale (family Liliaceae); used in the chronic treatment of gout. Inhibits microtuble formation.


(kŏl′chĭ-sēn′, kŏl′kĭ-)
A poisonous alkaloid, C22H25NO6, that is obtained from the autumn crocus and inhibits microtubule formation. It is used in medicine to treat gout and in plant breeding to produce polyploid plants.


An alkaloid isolated from autumn crocus-Colchicum autumnale used for long term control of gout Mechanism Colchicine blocks mitosis at metaphase by binding to the tubulin heterodimer, interfering with microtubule assembly Indications Management of gouty arthritis; used in research to arrest cells during mitosis–by disrupting the spindle, to visualize chromosomes


An alkaloid derived from bulbous plants of the genus Colchicum , such as the autumn crocus, used to treat GOUT and to induce chromosome doubling. The drug is on the WHO official list.


a poisonous alkaloid extracted from the corms of the crocus Colchicum autumnale that acts as a spindle inhibitor during NUCLEAR DIVISION and can thus be used to produce cells with double sets of chromosomes, due to NONDISJUNCTION. Mitosis is halted at the METAPHASE stage of division when the chromosomes are shortest and thickest. Colchicine is used routinely in the preparation of a KARYOTYPE.


A compound that blocks the assembly of microtubules-protein fibers necessary for cell division and some kinds of cell movements, including neutrophil migration. Side effects may include diarrhea, abdominal bloating, and gas.


[USP] An alkaloid obtained from Colchicum autumnale; used to treat gout.
References in periodicals archive ?
In this study, 22 (13 males and nine females) patients with FMF with colchicine resistance or intolerance, age ranging from 6 to 18 years, were included in Ege University Department of Pediatric Rheumatology.
Previous studies describe more common administration of NSAIDS in mild forms of the disease, whereas moderate to serious forms of PPS were treated with corticosteroids, or lately more frequently with colchicine in combination with NSAIDS (6,7).
Physicians have used colchicine to treat gout for decades, but they are often required to adjust the dose or interrupt treatment to address drug interactions or health conditions such as when patients are undergoing kidney dialysis.
Colchicine 0.4 mg/kg/day - nonligated (0.4 mgC) group (left side) and ligated (0.4 mgC-L) group (right side) (12 rats);
In this study, colchicine, 2-demethylcolchicine, 3-demethylcolchicine, 3-demethyl-N-formyl-N-deacetylcolchicine, colchifoline, 2-demethylcolchifoline, demecolcine, 2-demethyldemecolcine and 2-demethyl-[??]-lumicolchicine 12 were isolated from all the separated parts of C.
Production of amphidiploid plants of interspecific hybrid genotypes: There was no significant difference in amphidiploid plant production between 6 or 3 days of colchicine application.
Patients in the low-dose colchicine group were also more likely to use an NSAID other than naproxen at week 4 than were those in the naproxen arm (24.0 percent vs.
There was no relationship between the FMF disease severity score and the three stability indices, while the colchicine dose was related to all three stability indices (Table II).
The three-armed crossover trial will randomize patients to colchicine 0.6 mg twice a day, dapsone 150 mg/day, or azathioprine 2 mg/ kg per day for 6 months.
Despite systemic colchicine and sulfasalazine therapy, the disease progressed rapidly.
Prescription ColciGel[R], transdermal Colchicine, unlike colchicine pills, which are taken orally for gout, doesn't produce the often-intolerable gastrointestinal side effects due to its toxicity.